Ribeiro Maria-Joao, Vidailhet Marie, Loc'h Christian, Dupel Corinne, Nguyen Jean Paul, Ponchant Michel, Dollé Frédéric, Peschanski Marc, Hantraye Philippe, Cesaro Pierre, Samson Yves, Remy Philippe
URA CEA-CNRS 2210, Service Hospitalier Frédéric Joliot, 4, place du Général Leclerc, 91401 Orsay, CEDEX, France.
Arch Neurol. 2002 Apr;59(4):580-6. doi: 10.1001/archneur.59.4.580.
Measuring progression of Parkinson disease (PD) using positron emission tomography may help demonstrate the efficacy of neuroprotective treatments. To date, (18)F-dopa has been the gold standard to measure presynaptic dopaminergic function in PD, but this tracer might overestimate the rate of neuronal death in PD because its uptake also depends on dopamine turnover rather than exclusively on the density of dopaminergic terminals in the striatum. The latter might be assessed using newly developed ligands of the membrane dopamine transporter.
To compare the striatal uptakes of (18)F-dopa and (76)Br-FE-CBT, a dopamine transporter ligand, in patients with PD.
The striatal uptakes of (76)Br-FE-CBT and (18)F-dopa were compared using positron emission tomography in 10 patients with early PD and 8 with advanced PD. Correlation of uptakes with motor performance was investigated.
The reduction in (76)Br-FE-CBT binding to 43% of control values was more severe than the reduction in (18)F-dopa uptake (63% of control values) in the putamen of patients with early PD. No significant difference was found between either tracer's uptake in the putamen of patients with advanced PD. Motor performance was highly correlated to (18)F-dopa uptake, whereas correlation to (76)Br-FE-CBT binding was weak.
Uptake of (18)F-dopa may be up-regulated in early PD, suggesting a compensatory increase of dopamine synthesis in surviving dopaminergic terminals. Positron emission tomography dopamine transporter ligands and (18)F-dopa give complementary information on the presynaptic status of the nigrostriatal dopaminergic system and might be associated to investigate the efficacy of neuroprotective treatments in PD.
使用正电子发射断层扫描术测量帕金森病（PD）的进展可能有助于证明神经保护治疗的疗效。迄今为止，（18）F - 多巴一直是测量PD中突触前多巴胺能功能的金标准，但这种示踪剂可能高估了PD中神经元死亡的速率，因为其摄取还取决于多巴胺周转率，而不仅仅取决于纹状体中多巴胺能终末的密度。后者可使用新开发的膜多巴胺转运体配体进行评估。
比较PD患者纹状体对（18）F - 多巴和多巴胺转运体配体（76）Br - FE - CBT的摄取情况。
使用正电子发射断层扫描术比较了10例早期PD患者和8例晚期PD患者纹状体对（76）Br - FE - CBT和（18）F - 多巴的摄取情况。研究了摄取与运动表现的相关性。
早期PD患者壳核中（76）Br - FE - CBT与对照值相比减少至43%，比（18）F - 多巴摄取的减少（对照值的63%）更严重。晚期PD患者壳核中两种示踪剂的摄取之间未发现显著差异。运动表现与（18）F - 多巴摄取高度相关，而与（76）Br - FE - CBT结合的相关性较弱。
早期PD中（18）F - 多巴的摄取可能上调，提示存活的多巴胺能终末中多巴胺合成的代偿性增加。正电子发射断层扫描术多巴胺转运体配体和（18）F - 多巴可提供关于黑质纹状体多巴胺能系统突触前状态的补充信息，可能有助于研究PD中神经保护治疗的疗效。
